Challenges and Opportunities of biodefense contracts: a road map

Join us for another Life Science Breakfast!

Event Details

Location

swissnex San Francisco
730 Montgomery St., San Francisco, 94111 United States

Date

October 03, 2006 from 1:30 pm to 3:30 pm America/Los Angeles (UTC-07:00)

Life Science Breakfast

Bios

Speakers

Shauna Farr-Jones

Shauna Farr-Jones helps life science companies raise money via government grants and contracts. She provides proposal writing and strategic editing services to companies and universities in a variety of technology and therapeutic areas. Previously, she was an industry analyst at BioCentury Publications Inc., the leading biotechnology business newsletter, where she analyzed and wrote about strategic market and technology issues affecting biotechnology companies. She has conducted market research for HighTech Business Decisions on numerous drug discovery technologies. She was a post-doctoral fellow and research faculty member at the University of California, San Francisco, where she did research on protein structure determination. She earned a B.Sc. in Chemistry from Southampton University, UK, a Ph.D. in Biochemistry from Tufts University in Boston, and Certificates in Marketing and Finance from University of California, Berkeley Extension.

Piers Whitehead VaxGen, Vice President, Corporate and Business Development

Mr. Whitehead was formerly the vice president and head of Mercer Management Consulting’s San Francisco office. There he led marketing, strategy and manufacturing projects, with an emphasis on global health and vaccines, for clients that included the Global Alliance for Vaccines and Immunization, UNICEF and several private sector clients. During his 11 years with Mercer, Mr. Whitehead gained international prominence for his wide-ranging analysis of the biologics, pharmaceutical, global health and vaccine markets. His reports on the state of international vaccine development, including the analysis of manufacturing economics for the developing world, have become standard references for the field. Prior to joining Mercer he was a manager with London-based investment bank Robert Fleming Securities Ltd. There he led a team of seven analysts covering the European goods sector. Mr. Whitehead graduated from Oriel College in Oxford, England, receiving an M.A. in Classics, with honors, and a B.A. in Ancient and Modern Philosophy, with honors.

Jean-François Biry, CEO of DBV-Technologies

Mr. Biry started his career in the car industry and then joined the Edmond de Rothschild Group in 1986 as General Manager of the French Holding company. From 1995 to 2004 Mr. Biry was CEO of Cider Santé (1600 employees) , a company listed on the Nextprime market and a leading group providing services to the pharmaceutical industry (CS0,CRO,pharmaceutical depositary, regulatory affairs,etc.). Mr Biry also founded two pharmaceutical companies, CIPHARM and FORNET, the portfolio of which was made of mature reimbursed drugs purchased from big pharma companies, such as H M R,Beaufour and Wyeth, amongst others. From 2004 to 2005 Mr. Biry was Chairman of Laboratoires Codépharma , specialized in gynecology where he launched the first contraception patch, Evra (Johnson&Johnson; patent) in the French market. He holds an MBA from ESCP-EAP.

Moderator

Fred Dorey, special counsel in the Life Sciences practice group of the Cooley Godward Business department

Mr. Dorey represents a range of biotechnology, instrumentation and other technology companies at various stages of development from start-up and incorporation through licensing, corporate partnering and major collaboration transactions. He also has extensive experience negotiating clinical trial, sponsored research and intellectual property agreements. In addition, Mr. Dorey advises a number of major foundations, research institutions, and individuals regarding their participation in biomedical research endeavors, including investment, licensing and commercialization activities. Before joining the Firm, Mr. Dorey was the first president of the Bay Area Bioscience Center, a consortium of research universities, biotechnology companies and local governments organized to support bioscience development in Northern California. He also served as part-time in house counsel for several biotech companies including Tularik, Geron and Shaman. Previously, he had served as general counsel and corporate secretary for British Petroleum in San Francisco, where he was chief legal advisor for the Fortune 500-sized subsidiary that handled all BP oil exploration and production in the United States. He has also served as a regulatory enforcement lawyer and assistant office director for the Department of Energy in Washington DC. Mr. Dorey received a JD from the University of Southern California Law Center, where he was president of the Student Bar Association. Before law school he served as a White House Intern in the office of the Director of the Peace Corps in Washington DC. He received a BS in Engineering from University of California, Los Angeles. Mr. Dorey currently serves as a director of the American Liver Foundation, the World Affairs Council of Northern California, the Bay Area Bioscience Center, the San Francisco Boys Chorus and the National Kidney Foundation of Northern California. He is also a director of a privately held research instrumentation company. He is a member of the State Bar of California and the District of Columbia Bar.

Top